Lundbeck faces antitrust investigation
07 January 2010
James Nurton, London
The European Commission has opened an antitrust investigation into drugs company Lundbeck, based on information acquired during its sector enquiry into the pharmaceutical industry
The enquiry, completed last year, investigated alleged abuse of competition law by pharmaceutical companies, leading to delays in market entry of generic medicines.
In particular, the enquiry examined allegations about the evergreening of patents, patent clusters and reverse-payment deals.
When it was published in July,...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial